Last reviewed · How we verify
MEDI2338
At a glance
| Generic name | MEDI2338 |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI2338 CI brief — competitive landscape report
- MEDI2338 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI